Mood disorders are long-lasting conditions with inconsistent remission rates. Standard antidepressants fail many patients, cause side effects like weight gain and sexual problems, and act slowly. Newer drugs aim to work faster, with fewer side effects, and target symptoms poorly addressed by older medications, such as anhedonia, suicidal thoughts, insomnia, cognitive deficits, and irritability. These agents act on glutamate, GABA, orexin, and other receptors, offering more pharmacodynamic variety to personalize treatment. This review covers the clinical profiles of nine novel compounds—including psilocybin, esmethadone, and zuranolone—to help clinicians weigh benefits and risks for patients with different mood disorder symptoms and comorbidities.
Psilocybin shows promise for treating mood and anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, and substance use disorder, but significant evidence gaps remain. Current studies suggest psilocybin may alleviate depression, anxiety, obsessions, compulsions, and addictive behaviors, yet comparisons with standard antidepressants or anxiolytics are lacking, and optimal dosage, long-term efficacy, and safety are unclear due to trial limitations. Real-world implementation faces challenges including infrastructural requirements, personnel training, cultural stigma, and unresolved legal and ethical issues. Larger, more rigorous studies are needed to substantiate the evidence base before psilocybin can transition from research to clinical practice.